---
title: "Materialise NV Buys Back 44,178 Shares for EUR 206,562 at Average Price of 4.68 EUR"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274559680.md"
datetime: "2026-02-02T21:26:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274559680.md)
  - [en](https://longbridge.com/en/news/274559680.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274559680.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274559680.md) | [繁體中文](https://longbridge.com/zh-HK/news/274559680.md)


# Materialise NV Buys Back 44,178 Shares for EUR 206,562 at Average Price of 4.68 EUR

Materialise NV announced the repurchase of 44,178 shares under its share buy-back program, for a total consideration of 206,562 EUR at an average price of 4.68 EUR per share. The company currently holds 44,178 own shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Materialise NV published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Materialise NV (MTLS.US)](https://longbridge.com/en/quote/MTLS.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Materialise Updates Market on Ongoing €30 Million Share Buyback Program](https://longbridge.com/en/news/281082751.md)
- [Nuvalent CFO Alexandra Balcom sells $1.2 million Class A common shares](https://longbridge.com/en/news/281660994.md)
- [OMER S.p.A.: Resilient Fundamentals and Structural Growth Support Buy Rating Despite Softer FY26 Outlook](https://longbridge.com/en/news/281649119.md)
- [Cocrystal Pharma's CDI-988 Secures FDA Fast Track Designation To Prevent And Treat Norovirus](https://longbridge.com/en/news/281522861.md)
- [Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO](https://longbridge.com/en/news/281143495.md)